c-Met/HGFR
Gli inibitori di c-Met/HGFR mirano al Recettore del Fattore di Crescita degli Epatociti (c-Met), una tirosina chinasi coinvolta in processi cellulari come crescita, motilità e morfogenesi. La segnalazione di c-Met è implicata nella progressione del cancro, nella metastasi e nella resistenza alle terapie. L'inibizione di c-Met può interrompere la crescita e la diffusione del tumore, rendendo questi inibitori preziosi nella ricerca sul cancro. Presso CymitQuimica, offriamo inibitori di c-Met/HGFR per supportare la tua ricerca in oncologia, metastasi e terapie oncologiche mirate.
Trovati 128 prodotti di "c-Met/HGFR"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PHA-665752
CAS:<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Formula:C32H34Cl2N4O4SPurezza:97.05% - 98.82%Colore e forma:SolidPeso molecolare:641.61Capmatinib
CAS:<p>Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formula:C23H17FN6OPurezza:99.24%Colore e forma:SolidPeso molecolare:412.42PF-04217903
CAS:<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Formula:C19H16N8OPurezza:98.41% - 98.55%Colore e forma:SolidPeso molecolare:372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:<p>SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).</p>Formula:C25H23FN8O2S2·HClPurezza:97.95%Colore e forma:SolidPeso molecolare:587JNJ-38877605
CAS:<p>JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</p>Formula:C19H13F2N7Purezza:97.04% - 98.27%Colore e forma:SolidPeso molecolare:377.35Merestinib
CAS:<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Formula:C30H22F2N6O3Purezza:95% - 99.71%Colore e forma:SolidPeso molecolare:552.53MGCD-265 analog
CAS:<p>Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.</p>Formula:C26H20FN5O2S2Purezza:98.06% - 98.68%Colore e forma:SolidPeso molecolare:517.6Savolitinib
CAS:<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Formula:C17H15N9Purezza:98.12%Colore e forma:SolidPeso molecolare:345.36Capmatinib xHCl
CAS:<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Formula:C23H18ClFN6OPurezza:98.62% - 99.81%Colore e forma:SolidPeso molecolare:448.89SRI 31215 TFA
CAS:<p>SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.</p>Formula:C27H34F3N5O3Purezza:98.25% - 99.97%Colore e forma:SolidPeso molecolare:533.6Cabozantinib
CAS:<p>Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).</p>Formula:C28H24FN3O5Purezza:99.68% - 99.88%Colore e forma:SolidPeso molecolare:501.51(Z)-Semaxinib
CAS:<p>(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for</p>Formula:C15H14N2OPurezza:98.82% - ≥95%Colore e forma:SolidPeso molecolare:238.28Cabozantinib hydrochloride
CAS:<p>Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6</p>Formula:C28H25ClFN3O5Purezza:99.97%Colore e forma:SolidPeso molecolare:537.96BAY-474
CAS:<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Formula:C17H15N5Purezza:98.98%Colore e forma:SolidPeso molecolare:289.33Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Formula:C24H25ClFN5O3Purezza:98.56% - 99.9%Colore e forma:Off-White SolidPeso molecolare:485.94Amivantamab
CAS:<p>Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.</p>Purezza:97.24% (SEC-HPLC) - 99.74%Colore e forma:LiquidPeso molecolare:145.88 kDaFiclatuzumab
CAS:<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Purezza:95%Colore e forma:LiquidDavutamig
CAS:<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Purezza:98%Colore e forma:LiquidBafisontamab
CAS:<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Colore e forma:LiquidMAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Formula:C20H11Cl2N3OPurezza:98%Colore e forma:SolidPeso molecolare:380.23
